PDF(Pubmed)
Abstract：
Angiogenesis is a physiological process of forming new blood vessels that has pathological importance in seemingly unrelated illnesses like cancer, diabetes, and various inflammatory diseases. Treatment targeting angiogenesis has shown promise for these types of diseases, but current anti-angiogenic agents have critical limitations in delivery and side-effects. This necessitates exploration of alternative approaches like biomolecule-based drugs. Proteins, lipids, and oligonucleotides have recently become popular in biomedicine, specifically as biocompatible components of therapeutic drugs. Their excellent bioavailability and potential bioactive and immunogenic properties make them prime candidates for drug discovery or drug delivery systems. Lipid-based liposomes have become standard vehicles for targeted nanoparticle (NP) delivery, while protein and nucleotide NPs show promise for environment-sensitive delivery as smart NPs. Their therapeutic applications have initially been hampered by short circulation times and difficulty of fabrication but recent developments in nanofabrication and NP engineering have found ways to circumvent these disadvantages, vastly improving the practicality of biomolecular NPs. In this review, we are going to briefly discuss how biomolecule-based NPs have improved anti-angiogenesis-based therapy.
摘要：
血管生成是形成新血管的生理过程，在癌症等看似无关的疾病中具有病理重要性，糖尿病,和各种炎症性疾病。针对血管生成的治疗对这些类型的疾病有希望，但目前的抗血管生成药物在递送和副作用方面具有严重的局限性。这需要探索替代方法，如基于生物分子的药物。蛋白质,脂质，寡核苷酸最近在生物医学中变得流行，特别是作为治疗药物的生物相容性成分。其优异的生物利用度和潜在的生物活性和免疫原性特性使其成为药物发现或药物递送系统的主要候选者。基于脂质的脂质体已成为靶向纳米颗粒（NP）递送的标准载体，而蛋白质和核苷酸NP显示出作为智能NP的环境敏感性递送的希望。它们的治疗应用最初受到循环时间短和制造困难的阻碍，但纳米加工和NP工程的最新发展已经找到了规避这些缺点的方法。大大提高了生物分子NP的实用性。在这次审查中,我们将简要讨论基于生物分子的NP如何改善基于抗血管生成的治疗.
